Intellia Therapeutics reported this morning on the Phase 3 success of a gene editing treatment for hereditary angioedema, a disease that causes unpredictable, disfiguring and potentially dangerous swelling attacks. The biotech aims to have its …
Revolution Medicines threatens to sue Erasca over patent, efficacy claims
Earlier this month, a new cancer drug captivated patients and investors. Now the lawyers get their turn. On Monday, the biotech Erasca said it had



